The Patent Finder

5'-CAP-TRINUCLEOTIDE- or Higher Oligonucleotide Compounds and Their Use in Stabilizing RNA, Expressing Proteins in Therapy

BioNTech RNA Pharmaceuticals GmbH

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 12,281,1385'-CAP-TRINUCLEOTIDE- or Higher Oligonucleotide Compounds and Their Use in Stabilizing RNA, Expressing Proteins in Therapy
In force
 · High confidence
UsedRemaining
BioNTech SEIn forceHigh confidence
Application 17/371,9355'-CAP Compounds and Their Uses in Stabilizing RNA, Expressing Proteins and in Therapy
Abandoned
Abandoned Dec 5, 2024
BioNTech SEAbandonedAbandoned Dec 5, 2024
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by BioNTech RNA Pharmaceuticals GmbH.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited